EVIDENCE FILE 04 / MATRIX
Three Names, Three Different Evidence Problems
One copper complex, one variable blend, and one broad receptor agonist. Their shared aesthetic label is the least informative thing about them.
The short version
GHK-Cu, GLOW, and Melanotan II should not be ranked as three versions of the same idea. GHK-Cu is a defined copper-binding tripeptide with laboratory matrix evidence and a limited human topical record [1][4][7]. GLOW is a variable blend, usually combining GHK-Cu, BPC-157, and TB-500; its rationale is assembled from separate constituent literatures, and no controlled trial here tests the blend [8][9][10]. Melanotan II is a cyclic agonist at several melanocortin receptors. Its aesthetic effect is pigment signalling, accompanied by actions outside skin and a sparse human safety record [11][13][15].
For collagen-synthesis signalling, GHK-Cu is the only direct candidate in this set. GLOW includes it but cannot claim a blend effect without blend data. Melanotan II does not belong in a collagen pathway at all. None is dietary collagen, a source of vegan collagen, or evidence that a supplement replaces collagen. The useful comparison is therefore mechanism, evidence stage, and uncertainty—not which name sounds most aligned with appearance.
The comparison matrix
| Dimension | GHK-Cu | GLOW research blend | Melanotan II |
|---|---|---|---|
| What it is | Defined copper-binding tripeptide | Non-standardized mixture, usually GHK-Cu + BPC-157 + TB-500 | Defined cyclic alpha-MSH analog |
| Main aesthetic pathway | Fibroblast and extracellular-matrix signalling | Proposed matrix + vascular + cell-migration combination | MC1R-led melanocortin pigment signalling |
| Best evidence in this corpus | Reviews, cultured human fibroblasts, ex vivo skin, small topical studies [1][4][5][7] | Constituent reviews plus BPC-157 cell and animal work [8][9][10] | Small early human studies, animal mechanism work, and case reports [11][12][13][15] |
| What is not established | Large independent clinical confirmation or systemic use | Standard formula, blend efficacy, interaction, or combined safety | Long-term human safety or a collagen effect |
| Principal interpretation risk | Turning broad cell and gene signals into sweeping anti-aging claims | Treating ingredient plausibility as proven synergy | Treating visible pigmentation as skin health |
| Collagen relevance | Direct signalling research | Indirect through its GHK-Cu constituent | None established |
| Dietary or vegan-collagen relevance | None established | None established | None established |
Mechanism: matrix, mixture, and pigment
GHK-Cu has the most coherent connection to this hub’s angle. Cultured human fibroblasts increased collagen synthesis in response to the copper complex [7]. Reviews expand that picture to elastin, glycosaminoglycans, decorin, repair mediators, and matrix-regulating enzymes [4][6]. Delivery remains a limiting variable because a signal outside the skin barrier cannot act on deeper target cells [1][5].
GLOW takes that matrix story and adds two different proposals. BPC-157 activated VEGFR2-related angiogenic signalling in cell and animal models [10]. TB-500 is presented through actin and cell-migration biology, though evidence from full-length thymosin beta-4 may not transfer to the short fragment. The blend hypothesis is complementarity. The untested assumption is that the pieces remain stable, reach relevant tissue, and improve outcomes together.
Melanotan II uses another system entirely. MC1R signalling increases pigment production, while activity at other melanocortin receptors helps explain appetite and sexual effects [12][14][15]. Its presence in this hub maps the limits of an aesthetic category. A compound can change appearance through pigment without repairing matrix.
Evidence maturity: the gaps differ
GHK-Cu has the deepest relevant record of the three, but “deepest” is relative. The literature includes a foundational cell experiment, human skin penetration work, reviews of topical trials, and a controlled hair study of a combination product [1][3][4][5][7]. The record supports continued study and cautious topical interpretation. It does not support universal anti-aging language.
GLOW has the weakest product-level evidence because product-level evidence is absent. The 2026 overview warns that unapproved peptide enthusiasm often rests on animal repair results with little rigorous human safety information [8]. The BPC-157 review reaches a similarly guarded conclusion after finding sparse pilot work [9]. A mechanistic vascular study is informative about BPC-157 and silent about whether GLOW works [10].
Melanotan II has a different kind of thinness. Small controlled human work confirms biological activity [15], but later safety information in this selection includes individual cases rather than large surveillance cohorts [11][13]. That record can flag plausible harm and cannot estimate how often it occurs. Evidence maturity is not a single score: each file is incomplete in a different direction.
What each is actually studied for
GHK-Cu is studied around collagen production, matrix remodelling, wound biology, topical skin appearance, penetration, gene expression, and hair-related outcomes [1][2][3][4][5][6][7]. These themes justify its lead position while requiring care about model and formulation.
GLOW is discussed as a combined repair concept. GHK-Cu supplies skin and matrix relevance; BPC-157 supplies much of the experimental vascular and connective-tissue rationale; TB-500 supplies a migration and repair narrative. The blend itself has not been tested against its components [8][9][10]. Its name describes a hoped-for appearance, not a validated endpoint.
Melanotan II is studied through melanocortin biology: pigmentation, appetite, and centrally mediated sexual effects [12][14][15]. The recent case literature adds oral pigmentation and renal harm signals [11][13]. It is included solely within that documented aesthetic and safety context.
The boundaries matter more than the overlap. Only GHK-Cu directly addresses collagen-related signalling. Only GLOW is a mixture. Only Melanotan II is primarily a pigment-pathway agonist. None supplies collagen as nutrition.
The decision rule for reading claims
For GHK-Cu, ask whether a statement comes from cells, prepared human skin, a small topical trial, a combination product, or a review. Then ask whether the tested formulation matches the claim. For GLOW, ask whether the evidence studied the actual blend. In this corpus, it did not. For Melanotan II, ask whether a visible pigment effect is being presented as skin health and whether a small study or case report is being stretched into certainty.
The same rule applies across all three: identify the entity, model, endpoint, and missing comparison. A pathway can be real while a product claim remains unproved. A case report can be important while incidence remains unknown. A review can summarize available findings while independent replication remains limited.
The result is not a winner. It is a map of appropriate confidence. GHK-Cu warrants the most confidence for a narrow matrix-signalling statement. GLOW warrants interest as a combination hypothesis and skepticism as a product. Melanotan II warrants recognition as a potent melanocortin research compound and caution against cosmetic reduction. Those conclusions are narrower than marketing and better aligned with the record.